(Q37566249)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

review article

1 reference

title

Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Tessa Holyoake

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

J M Goldman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

C Jamieson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

R Mesa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

T Mughal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

F Pellicano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

D Perrotti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

R Skoda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

A M Vannucchi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

1 reference

30 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

1708-1715

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Chronic myeloid leukaemia as a model of disease evolution in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

BCR-ABL-transformed GMP as myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Dynamics of cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

PML targeting eradicates quiescent leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Characterization of murine JAK2V617F-positive myeloproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Polycythemia vera is not initiated by JAK2V617F mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

JAK signaling globally counteracts heterochromatic gene silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

5-Azacitidine has limited therapeutic activity in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Nuclear translocation of urokinase-type plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

MicroRNA signatures in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

MicroRNA expression profile in granulocytes from primary myelofibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Aberrant expression of microRNA in polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

New insights into the pathogenesis and treatment of chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

The yin and yang of lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

7 January 2021

Stem cells in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

7 January 2021

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

7 January 2021

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

7 January 2021

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

7 January 2021

Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.142

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.142

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641523%20AND%20SRC:MED&resulttype=core&format=json

release_uf5om6zoxjb27cmfwu2hrvzfi4

3 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uf5om6zoxjb27cmfwu2hrvzfi4

24 November 2022

mapped directly with Wikidata item

1 reference